ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging. The study, by scientists at AgeX and BioTime, in collaboration with Insilico Medicine, utilized artificial intelligence (AI) technology to parse millions of gene expression data points to decipher the complex mechanisms controlling natural tissue regeneration. The results, published in the peer-reviewed scientific journal Oncotarget, showed that the candidate genes are expressed differently in tissues early in development when they are capable of regeneration compared to later in life when regeneration can no longer take place. Surprisingly, some of the genes, including one highlighted in the study, COX7A1, displayed a rare profile of being nearly universally dysregulated in diverse types of cancer. The discoveries may lead to novel strategies to induce Tissue Regeneration (iTR^TM) in the context of trauma or age-related degenerative disease, as well as treat and diagnose cancer.

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX) announced today that Chief Executive Officer Michael D. West, Ph.D., is participating on a roundtable panel at Termis Americas’ annual conference & exhibition on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, North Carolina. Dr. West will describe the AgeX product pipeline, in particular, the emerging field of induced tissue regeneration (iTR). Dr. West’s presentation will be available for viewing at www.agexinc.com....

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX) announced today that VP of New Scientific Discovery Aubrey de Grey, Ph.D. is participating on a panel at the FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London. ...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announced today that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is giving an interview as part of The Economist magazine’s conference, “The Business of Longevity: Health Innovation for An Ageing World,” on Friday, October 27 in Hong Kong. ...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announces that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is participating in a fireside chat at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston. ...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announced today that it has closed its round of equity financing, raising net proceeds of $10 million, valuing AgeX at approximately $68 million post-money. Post-closing, BioTime owns approximately 85% of the outstanding shares of AgeX. The financing, first announced on August 2, 2017, is expected to fund AgeX’s general operations and product development well into 2019, while saving BioTime approximately $5 million annually on these programs and associated operational expenses. The majority of the investors participating in the financing were new to the BioTime group of companies....

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that CEO Michael D. West, Ph.D., will deliver the keynote presentation at the RAAD Festival 2017 (RAADfest), a large annual gathering of life extension experts, August 9-13, at the Town and Country Resort & Convention Center in San Diego, California. Dr. West will deliver the presentation titled “Telomeres, Stem Cells, and iTR: Redefining Human Aging” on Wednesday, August 9th at 7:00pm PDT. The presentation will be made available on the Company’s website....

ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 2, 2017-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today reported that it has successfully raised $10 million in equity financing to fund its operations. Following the financing, BioTime continues to own about 87% of AgeX's outstanding shares. The financing is expected to fund preclinical development at AgeX as well as building the company's operational infrastructure. The financing may also lead to a registration and distribution of a to-be-determined percentage of the AgeX shares to BioTime shareholders, after which AgeX would trade as a public company....